Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInventory AverageInvested Capital

Zhengye Biotechnology Holding (ZYBT) Enterprise Value (2023 - 2025)

Zhengye Biotechnology Holding has reported Enterprise Value over the past 3 years, most recently at $712717.6 for Q4 2025.

  • Quarterly Enterprise Value fell 89.45% to $712717.6 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $712717.6 through Dec 2025, down 89.45% year-over-year, with the annual reading at $922212.1 for FY2025, 86.11% down from the prior year.
  • Enterprise Value was $712717.6 for Q4 2025 at Zhengye Biotechnology Holding, down from $2.7 million in the prior quarter.
  • Over five years, Enterprise Value peaked at $6.8 million in Q4 2024 and troughed at $712717.6 in Q4 2025.
  • The 3-year median for Enterprise Value is $4.0 million (2023), against an average of $3.9 million.
  • Year-over-year, Enterprise Value grew 28.0% in 2024 and then plummeted 89.45% in 2025.
  • A 3-year view of Enterprise Value shows it stood at $5.3 million in 2023, then increased by 28.0% to $6.8 million in 2024, then plummeted by 89.45% to $712717.6 in 2025.
  • Per Business Quant, the three most recent readings for ZYBT's Enterprise Value are $712717.6 (Q4 2025), $2.7 million (Q2 2025), and $6.8 million (Q4 2024).